Our renlt. demoutrate aa advaataae 01 aprotlain liven U coDtmuoa. lDtUaloD over bola. appUcaUoD lD OLT.
In OLT, hyperfibrillolyail h.u been recopized .. an important ClUM of intra-and poet.operative bleedin& (1-.. 1), intluencinI both the ahort-and lon,-term outcome (4, 6). PreviOUI inVflltigationa have indicated that hyperfibrinolyaia ia due to an increue olüuue-type pwminopn activator (t-PA)· activ-I Addreu COrNIpondence 00: Dr. med. G. Himmelnicb. Gaubiua Laboratory TNO, P.O. BoI 430, 2300 AR Leiden, Tb. NetherWtd..
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• AbbNViationt: «rAP, «r antiplu.min; AT 111, u titluombin 111; B, bolue POUP of aprotinin app1ieation; Cl-inb, Cl -iI'Ihibitor; FPP, rn.h frozen plalzu; I, inlueion POUP of IPz'otinin application; KIU ity (1, 3) and a concomitant increue of urokinue-type pluminogen aetivator (u-PA) activity (1) .
Aprotinin (Traaylol, Bayer, Leverkueen, Germany), a parenterally applied proteinue inhibitor from bovine lune (6-8), inhibite plumin, kallikrein, tryp&in, ud to IOme enent human urokinaM (7) . Tb. toxicity of aprotinin iI ennmely low (7), ud even hieb. doIOI are well tolerated (6, 9) . AI randomiJed et:udi. in cardiac l\lI"Pry bave demonatrated ailnificantly reducecl tranafuaion requirementa when aprotinin w . . . dmin; •• tered durine lurpry (10, ll ), we teated ita application in patienta undergoing OLT. Boh" application of 0.6 MüI. kaIli· krein inactivator unita (KIU) aprotinin liven three timet durlnJ OLT led. to reductiona in blood product requiremant and in the increue olt·PA activity (1 ) .. compared with tbe reporta of other inveetipton (2, 3, 12) . Nevertbeleu, thrombelutopphy (TEG) ahowed aipu oi hyperfibrinoly.i. in moo of the OLT., in apite ol aprotinin bolua application.
In the prMOnt etudy, we have inveetipted tbe efrett of two different aprotinin reaU:nena on tbe helDOltatic ehanpa ud blood product roquitementa in 23 OLTa.
MATERIALS AND METHODS
In an open, proepective, and rudomized Itudy 23 ~tiente witb terminal liver diIeue (Table 1 Tbe (ollowin, parametera wen meuured uaini oommereially avail-.!Ible kib: protA;n C (PC) aetivity (Boehringer, MannlMim, Gnm. ny), antithrombin 111 (AT 111) ACtivity, pluminopn ACtivity, a t-antiplumin (a,-AP) activity, Cl-inhibitor (C1-inh) activity (all: Rehring Werke AG, MarbW'J, Germany), fibrinogen according to Clauaa (HoffmannLaRoche, Baael Switierland). 1--PA and P AI activitiea wen determined by chromogenie eubetratll methoda, where .. t-PA antigen w .. me .. -uNd Ulini a solid-phase enzyme immunouaay (alI: Kabi, Stockholm, Sweden). Thrombin-antithrombin III (TAT) compler.ea were determined by enzyme immunouaays (Behrinperke AG, Muburt, Germany). Aprotinin w .. eltimated by ELiSA u previoWlly described (16 In TEG, hyperfibrinolysia waa stated in 7 out of 13 OLTs in the bolus group but ooly in 1 out of 10 OLTs in the infusion group (Fig. 1) . Levels oft·PA activity increaaed in both groupa during the anhepatic phase, reaching their peaks immediately be(ore reperfusion. These muima, however, were significantly higher in the bolus group (Fig. 2) . Tbe t-PA antigen levels in plaama did not differ between the two groups. In both groupa PAI levels increased alter reperfusion to comparablelevela (Fig.  3) . The cour&e of C1-inh did not differ for either group (Fig. 3) . The levela of a2-AP were higher in the infusion group, reaching significance only 10 min after the beginning o( the anhepatic phaae and 12 hr alter reperfusion (Fig. 4) . Plaaminogen concentration ahowed no ditference in either group (Fig. 4) . TAT complens showed significantly higher levels in the infusion group prior to the anhepatic phase and at ita oneet end alter reperfusion (Fig. 5) , Similarly, fibrinogen levels were higher in the bolus groUp shortly before the anhepatic phaae and alter reperfusion (Fig. 5) . The course o(PC and AT III activities did not differ in the two groupa (Fig. 6 ). Aprotinin levels were significantly higher in the infusion group (Fig. 7) .
In the perfusate the comparilOn of different hemostatic parameters betwe~m tbe groups revealed a aignificantly lower level oft-PA antigen and a tendentiously lower level in t-PA &etivity in the infusion group while activity o( the inhibitors PAI and a z-AP waa significantly increased in thia group. All otber parameten in the perfuaate were comperable in both groups (Table 3 ).
D1SCUSSION
Our previous e:rperience (1) prompted UI to postulate a beneficial effeet of aprotinin bolus application on the course of OLT, but signs of hyperfibrinolysis as meaaured by TEG Were .till preaent in most patienta undergoing OLT. Here, we have investigated the effeet o( intermittent bolus vereus continuous infusion application of aprotinin during the course of 23 OLTa in an open, prospective, and randomized study.
We conrll'tDed previous inveetigations suggeating a beneficial effect of aprotinin bolus application in reducing signs of hyperfibrinolyeis end bleeding complications in patientl undergoing OLT (1) .
• ..... t. Aprolinin levels were higher in the infusion group during the whole length of the ÜL Ts (Fig. 7) . Signs o( hyperfibrinolysis. according to TEG and increased t · PA aetivity (rigs. 1 and 2) oceurred more often in the bolus group especially before and after reperfusion, whereas PAI and a 2·A P levels (Figs. 3 and 4) were lower during the anhepatie phase and after repe rfusion in the infusion group, respe<:tively. These results suggest that higher apfotinin levels maintained by continuou. infusion re· duee plasminogen activator aetivity in plasma and diminish signs of hyperfibrinolysis in the infusion group.
After reperfusion a more pronounced inerease of TAT eorn· plexes and a coneomitant decrease of fibrinogen levels in the infusion group indieate an inereased prothrombin aetivation. Higher aprotinin levels may shift the hernostatic balance to· ward coagulation. As on the other hand aetivities of pe, AT 111 , and CI · inh were nOl seriously decreased in either group no aceelerated eonsumption of eoagulation factor inhibitors eould be suspe<:ted.
". Dur results showed higher blood product requiremenlS during OLT in the bolus group but not to a significant level. All 23 patienUJ sre still alive. and onl y one woman of the bolus group and one woman of the infusion group needed retransplantation because of seyere host·versus·graft resetioDs. Neither had he· patie artery thrombosis. Our preyious investigations of the perfu88te showed signifieantly higher TAT eomplexes and signiricantly lower aetivities of the protease inhibitors pe, AT 111 , and C I · inh when compared with the systemic cireulation 5 min before reperfusion. This indieates increased prothrombin acti · vslion and a coDsumption of inhibitors in the graft liver (I). Furthermore. parameters of actiYAted phElgC)l:yteli such EIS elal' tase and cathepsin 8 were found to be signifieantly eleyated in the perfusate (17) . In addition, it hall recently Ileen demon· strßted that aprotinin exerts a protf!(:tive effect on ischemic hepatocellular damage oceurring in the rat liver.transplant model (/8). We wondered whether considering these results higher systemie leyels of aprotinin in the reperfusion phose wilJ
.. • . ,
, , " 7 change hemoatatic parameters of the gratt liver perfuaate. Indeed, t-PA antigen and activity were lower and PAI and a2-AP activitiea ware higher in tbe perfueate ofthe infusion group.
In vitro atudies ahowed DO .ffeet ol different amount8 of aprotinin in t·PA end PA! activity assays (not publiahed). Presuming that hilh 8y1temic aprotinin levels lU'e mucin, endothelial damage in the flushed graft liver, the lower t·PA activity and antipn levela in the perfueate cu be nplained. In addition, it hu to be diecuued whether t-PA liberation is reduced by inhibition or kallikrein, a potent stimulator or t·PA release (19) . However, the diminished t-PA releue in tbe graft liver did not resu1t in alower t·PA level in the aystemic circulation after reperfuaion.
Parameten of thrombin formation and protease inhibiton did not differ in the perfueate and the syatemic circuJ.ation.
In summary, aprotinin application by infusion resulte in sienificantly diminished signs of hyperiibrinolyais end a leuer inCnlue in t-PA activity intraoperatively. aprotinin given in higher concentrationB may influence the hemoatatic balance toward hypercoagulation. A beneficiaJ effect of aprotinin for the pnlvention of endothelial damage in the graft liver il auggelted.
